Miraclin (Doxycycline Hyclate)

Doxycycline hyclate, the active ingredient in Miraclin, is a tetracycline antibiotic presented as an oral tablet for systemic use. It treats a range of bacterial infections, including respiratory, urinary, skin, and certain sexually transmitted infections, in both adult and pediatric patients under medical supervision.

GNH USA supplies Miraclin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products that meet European regulatory standards through robust supply chain management and regulatory compliance, and timely delivery.

Miraclin (doxycycline hyclate) is employed to treat bacterial infections across several organ systems. - Respiratory tract infections: reduces bacterial load and alleviates symptoms such as cough and fever. - Urinary tract infections: eradicates susceptible uropathogens and helps resolve dysuria and frequency. - Skin and soft‑tissue infections (including acne): limits bacterial proliferation, improving lesions and preventing scarring. - Chlamydial infections: eliminates Chlamydia trachomatis, preventing complications and transmission. - Lyme disease: targets Borrelia burgdorferi to halt disease progression in early stages.

Adverse reactions to Miraclin vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Vomiting: occasional expulsion of stomach contents. - Diarrhea: loose stools, sometimes watery. - Photosensitivity: increased skin sensitivity to sunlight. - Abdominal pain: cramping or discomfort. - Esophagitis: irritation of the esophageal lining.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with airway compromise. - Stevens‑Johnson syndrome: rare skin blistering and mucosal involvement. - Hepatic toxicity: elevated liver enzymes or hepatitis. - Intracranial hypertension: headache and visual disturbances. - Clostridioides difficile‑associated diarrhea: severe colitis. - Severe skin reactions: toxic epidermal necrolysis.

Before prescribing Miraclin, clinicians should consider several precautionary measures. - Pregnancy: Category D; use only when benefits outweigh potential fetal risks. - Breastfeeding: drug is excreted in milk; evaluate risk versus benefit. - Renal impairment: dose adjustment may be required in reduced kidney function. - Sun exposure: advise patients to use sunscreen and protective clothing due to photosensitivity. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature below 25°C: keep in original packaging, protect from moisture and light.

Miraclin can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Antacids containing aluminum, calcium or magnesium: chelate doxycycline and markedly reduce absorption. - Iron supplements: bind doxycycline, decreasing its bioavailability. - Warfarin: may potentiate anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - Oral contraceptives: doxycycline may reduce hormonal efficacy, risking unintended pregnancy. - Cyclosporine: concurrent use can raise cyclosporine levels, requiring monitoring.